Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multiple Dose, Randomized, Three-Period Crossover Study in Healthy Volunteers to Evaluate the Effect of co-Administration of Amantadine 100 mg BID and Oseltamivir 75 mg BID on the Pharmacokinetic Properties of Amantadine and Oseltamivir.

NCT00416962 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00416962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00416962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multiple Dose, Randomized, Three-Period Crossover Study in Healthy Volunteers to Evaluate the Effect of co-Administration of Amantadine 100 mg BID and Oseltamivir 75 mg BID on the Pharmacokinetic Properties of Amantadine and Oseltamivir.
Lead sponsor
Novartis
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2006
Completion date
December 31, 2006
Enrollment
18
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy